“The proposed US tariffs on generic imports, which are not India-specific, are unlikely to significantly impact Indian pharma. Manufacturing in India is 40-60% cheaper, and setting up US plants would take 3-4 years for approvals, making it economically unviable for generics. This implies minimal long-term impact on the Indian Pharma sector, despite initial market reaction.”